What is doxepin and how does it work?

What is Doxepin and How Does It Work

Doxepin is a tricyclic antidepressant medication that, at low doses (3-6 mg), functions primarily as a highly selective histamine H1 receptor antagonist to treat insomnia, while at higher doses (25-100 mg) it acts on multiple neurotransmitter systems to treat depression and anxiety. 1

Mechanism of Action

Low-Dose Doxepin (3-6 mg) for Insomnia

At low doses, doxepin works through a highly selective and potent blockade of histamine H1 receptors 2, 3. This mechanism is distinct from its antidepressant effects and explains its efficacy in promoting sleep initiation and maintenance. The H1 receptor antagonism reduces wakefulness-promoting histaminergic signaling in the brain, thereby facilitating sleep 2.

Key pharmacological properties at low doses:

• Approximately 8-fold more potent than traditional antihistamines like mepyramine at H1 receptors 4
• Minimal effects on other receptor systems at these doses
• No significant anticholinergic, serotonergic, or adrenergic activity at 3-6 mg 2

Higher-Dose Doxepin (25-100 mg) for Depression/Anxiety

At therapeutic antidepressant doses, doxepin's mechanism becomes more complex 1:

Primary mechanisms:

• Inhibits norepinephrine reuptake at synapses, preventing deactivation and increasing adrenergic neurotransmission 1
• Blocks serotonin (5-HT) receptors centrally, contributing to mood regulation 5
• Antagonizes histamine H1 and H2 receptors, providing sedative effects 4
• Anticholinergic effects on muscarinic receptors, though less potent than atropine 4

The FDA label explicitly states that while the exact mechanism is not definitively known, the clinical effects are attributed "at least in part, to influences on the adrenergic activity at the synapses so that deactivation of norepinephrine by reuptake into the nerve terminals is prevented" 1.

Clinical Applications

For Insomnia (Low-Dose)

The American Academy of Sleep Medicine (2017) suggests using doxepin 3-6 mg for sleep maintenance insomnia 6. The evidence demonstrates:

• Clinically significant improvements in wake after sleep onset (WASO), total sleep time (TST), and sleep efficiency (SE) 6
• Minimal improvement in sleep onset latency 6
• Effects evident after single dose administration and maintained for up to 12 weeks 2
• No evidence of physical dependence or rebound insomnia upon withdrawal 2

The 2019 VA/DoD guidelines note that low-dose doxepin should be considered when patients are unable or unwilling to receive cognitive behavioral therapy for insomnia (CBT-I), which remains first-line treatment 7.

For Depression/Anxiety (Higher-Dose)

FDA-approved indications at 25-100 mg doses include 1:

• Psychoneurotic patients with depression and/or anxiety
• Depression/anxiety associated with alcoholism
• Depression/anxiety associated with organic disease
• Psychotic depressive disorders with associated anxiety

The drug combines antidepressant activity with sedative effects, making it particularly useful for depressed patients with sleep disturbances and anxiety 8.

Safety Profile

Low-Dose (3-6 mg)

• Minimal adverse effects beyond placebo in clinical trials 6
• Mild increase in somnolence at 6 mg dose (4% risk difference) 6
• No significant next-day impairment on cognitive testing 6
• No black box warning for suicide risk at hypnotic doses, though risk cannot be excluded 7

Higher-Dose (25-100 mg)

• Black box warning for increased suicidality risk in children, adolescents, and young adults 1
• Common side effects: dry mouth, drowsiness, constipation 8
• Contraindicated in glaucoma and urinary retention 1
• Cardiotoxic in overdose, similar to other tricyclics 8

Important Clinical Considerations

Doxepin is NOT a CNS stimulant or monoamine oxidase inhibitor 1. It does not produce euphoria and has not demonstrated physical tolerance or psychological dependence characteristic of addictive compounds at therapeutic doses 1.

The drug's dual utility at different dose ranges makes it unique—low doses exploit selective H1 antagonism for insomnia, while higher doses leverage multiple neurotransmitter effects for mood disorders. This dose-dependent mechanism explains why a 3 mg dose for insomnia has a completely different side effect profile than a 75 mg dose for depression.